Lin BioScience, Inc. (TPEX:6696)
Taiwan · Delayed Price · Currency is TWD 267.00
-2.00 (-0.74%)
Oct 31, 2025, 2:59 PM CST
Lin BioScience Company Description
Lin BioScience, Inc., a drug development company, develops therapies for oncology, ophthalmology, and metabolic diseases.
Its product pipeline includes LBS-008, an oral therapy for dry age-related macular degeneration (Dry AMD)and stargardt diseases (STGD1), which is under Phase 3 clinical trial to evaluate safety and efficacy in adolescent STGD1 and under phase 2 or phase 3 clinical trial to evaluate safety and efficacy in Dry AMD; LBS-007, a natural non-ATP CDC7 inhibitor for the treatment of cancers; LBS-002, an anti-tubulin to treat primary and metastatic brain tumors; and LBS-009, an oral therapy for the treatment of non-alcoholic fatty liver disease and type 2 diabetes.
The company is headquartered in Taipei, Taiwan.
Lin BioScience, Inc.
| Country | Taiwan |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Zhengqi Wang |
Contact Details
Address: No. 68, Zhongxiao East Road Taipei, 110 Taiwan | |
| Phone | 886 2 8780 5008 |
| Website | linbioscience.com |
Stock Details
| Ticker Symbol | 6696 |
| Exchange | Taipei Exchange |
| Fiscal Year | January - December |
| Reporting Currency | TWD |
| ISIN Number | TW0006696008 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Zhengqi Wang M.B.A., Ph.D. | President, CSO and Director |
| Serena Chen | Chief Financial Officer |